What is the current treatment of patients with essential thrombocytopenia and other myeloproliferations accompanied with thrombocytopenia, and what can be the predictive sign of the risk of thrombosis in such patients – a report from the registry of patients treated by Thromboreductine^®

Czech version

Authors: M. Penka ¹; J. Schwarz ²; T. Pavlík ³; R. Pytlík ⁴; M. Do ubek ⁵; P. Ďulíček ⁶; J. Kissová ¹; A. Hluší ⁷; M. Schutzova ⁸; O. Černá ⁹; Y. Brychtová ¹; T. Szotkowski ⁷; Z. Volková ³; J. Seghetová ¹⁰; V. Vozobulová ⁸; I. Hadačová ¹⁰; I. Hochová ¹⁰; J. Voglová ⁶; L. Dušek ³
Authors‘ workplace: Oddělení klinické hematologi e FN Brno, pracoviště Bohunice, přednosta prof. MUDr. Miroslav Penka, CSc. ¹; Klinický úsek Ústavu hematologi e a krevní transfuze Praha, přednosta doc. MUDr. Petr Cetkovský, Ph. D. ²; Institut bi ostatistiky a analýz MU Brno, přednosta doc. RNDr. Ladislav Dušek, CSc. ³; I. interní klinika 1. lékařské fakulty UK a VFN Praha, přednosta prof. MUDr. Pavel Klener, DrSc. ⁴; Interní hemato onkologická klinika LF MU a FN Brno, pracoviště Bohunice, přednosta prof. MUDr. Jiří Vorlíček, CSc. ⁵; Oddělení klinické hematologi e II. interní kliniky LF UK a FN Hradec Králové, přednosta prof. MUDr. Jaroslav Malý, CSc. ⁶; Hemato- onkologická klinika Lékařské fakulty UP a FN Olomo uc, přednosta prof. MUDr. Karel Indrák, DrSc. ⁷; Hematologicko- onkologické oddělení FN Plzeň, přednosta prim. MUDr. Vladimír Koza ⁸; Oddělení klinické hematologi e FN Královské Vinohrady Praha, přednosta doc. MUDr. Tomáš Kozák, Ph. D. ⁹; Oddělení klinické hematologi e FN Motol, Praha, přednostka prim. MUDr. Ivana Hochová ¹⁰
Published in: Vnitř Lék 2008; 54(7-8): 775-782
Category: Original Contributions

Overview

The registry of patients treated with Thromboreductine^® (anagrelid) in the contributing centres in the Czech Republic has been updated with data on the patients receiving this medication since 2004. The original purpose of the registry was to record responses to Thromboreductine^® therapy and adverse drug reactions in patients with essential thrombocythemia. However, data on additional Ph negative myeloproliferations, as well as data on cytoreductive therapies other than exclusively that using Thromboreductine^® has also been recorded in the course of its compilation, including data on combined regimes. At present, the database contains data on 421 patients, and valid conclusions can be drawn if the level of data filling is enhanced. Evaluation has been currently focused on the analysis of the risk of development of clinical symptoms of thrombosis and on the standards of treatment from the viewpoint of the achieved treatment response. Analyses of data from the registry corroborate the special importance of the proof of JAK2 mutation, and of the test for factor V Leiden mutation, and of protein of S for the assessment of the risk of thromboembolic complications. The output of the analysis confirms that anagrelid is a very efficient thromboreductive agent the administration of which is associated with a low incidence of non‑serious adverse effects (10.9%). However, in spite of a fast response to therapy, the therapeutic goal consisting in the reduction of the platelet count below 400 (or below 600) × 10⁹/l, i.e. the complete (or partial) treatment response, is relatively slow to achieve. This is likely to be due to lack of radical corrections in the dosage of the drug for different reasons.

Key words:
essential thrombocythemia – myeloproliferations – anagrelid (Thromboreductine^®) – registry – JAK2 mutation – thrombophilia

Sources

1. Barbui T, Barosi G, Grossi A et al. Practice guidelines for the therapy of essenti al thrombocythemi a. A statement from the Itali an Soci ety of Hematology, the Itali an Soci ety of Experimental Hematology and Itali an Gro up for Bone Marrow Transplantati on. Haematologica 2004; 89: 215– 232.

2. Brière JB. Essenti al thrombocythemi a. Orphanet J Rare Dis 2007; 2– 3: 1– 17.

3. Cortelazzo S, Finazzi G, Ruggeri M et al. Hydoxyure a for pati ents with Essenti al Thrombocythemi a and a high risk of thrombosis. N Engl J Med 1995; 332: 113.

4. Costello R, Callaghan TO, Sébaho un G. Traitement de la thrombocythémi e essenti elle. La revue de médecine interne 2005; 26: 947– 955.

5. Elli ott MA, Tefferi A. Interferon-alfa therapy in Polycythemi a Vera and essenti al Thrombocythemi a. Semin Thromb Hemost 1997; 23: 463.

6. Fruchtman SM, Petitt RM, Gilbert HS et al. Anagrelide Study Gro up: Anagrelide: analysis of long‑term efficacy, safety and le ukemogenic potenti al in myeloproliferative disorders. Le ukemi a Rese arch 2005; 29: 481– 491.

7. Green A, Campbell P, Buck G et al. The Medical Rese arch Co uncil PT1 Tri al in Essenti als Thrombocythemi a. Blo od 2004; 104/ 11: 5a– 6a (Abstr 6).

8. Hoffman R, Prchal JT, Samuelson S et al. Philadelphi a Chromosome- Negative Myeloproliferative Disorders: Bi ology and Tre atment. Bi ology of Blo od and Marrow Transplantati on 2007; 13: 64– 72.

9. Jaffe ES, Harris NL, Stein H et al (eds). World he alth organizati on classificati on of tumo urs. Pathology and genetics of tumo urs of haematopo i etic and lympho id tissues. Lyon: IARC Press 2001: 352.

10. Ka ushansky K. The chronic myeloproliferative disorders and mutati on of JAK2: Damesek’s 54 ye ar old speculati on comes of age. Best Pract Res Clin Haematol 2007; 20/ 1: 5– 12.

11. Kralovics R, Passamonti F, Buser AS et al. A Gain- of- Functi on Mutati on of JAK2 in Myeloproliferative Disorders. N Engl J Med 2005; 352: 1779– 1790.

12. Kralovics R, Skoda RC. Molecular pathogenesis of Philadelphi a chromosome negative myeloproliferative disorders. Blo od Rev 2005; 19: 1– 13.

13. Landoffi R, Rocca B, Patrono C. Bleeding and thrombosis in myeloproliferative disorders: mechanism and tre atment. Crit Rev Oncol Hematol 1995; 20: 203– 222.

14. Michi els JJ, Kutti J, Stark P et al. Di agnosis, pathogenesis and tre atment of the myeloproliferative disorders essenti al thrombocythemi a, polycythemi a vera and essenti al megakaryocytic granulocytic metaplasi a and myelofibrosis. Netherlands J Med 1999; 54: 46– 62.

15. Michi els JJ, Barbui T, Finazzi G et al. Di agnosis and tre atment of Polycythemi a Vera and possible future study designs of the PVSG. Le uk Lymphoma 2000; 36: 239– 253.

16. Michi els JJ, Thi ele J. Clinical and pathological criteri a for the di agnosis of essenti al thrombocythemi a, polycythemi a vera and idi opathic myelofibrosis (agnogenic myelo id metaplasi a). Int J Hematol 2002; 76: 133– 145.

17. Michi els JJ, DeRaeve H, Hebeda K et al. WHO bone marrow fe atures and Europe an clinical, molecular, and pathological (ECMP) criteri a for the di agnosis of myeloproliferative disorders. Le ukemi a Res 2007; 31: 1031– 1038.

18. Murphy S, Peterson P, Iland H et al. Experi ence of the Polycythemi a Vera Study Gro up with essenti al thrombocythemi a: a final report on di agnostic criteri a, survival, and le ukemic transiti on by tre atment. Semin Hematol 1997; 34: 29– 39.

19. Penka M, Schwarz J, Pytlík R et al. Doporučený postup di agnostiky a terapi e esenci ální trombocytemi e a trombocytemi e provázející myeloproliferativní onemocnění. Vnitř Lék 2005; 51: 741– 751.

20. Penka M, Schwarz J, Pavlík T et al. Esenci ální trombocytemi e a další myeloproliferace s trombocytemi í v údajích registru paci entů léčených Thromboreductinem® do konce roku 2006. Vnitř Lék 2007; 53: 653– 661.

21. Petrides PE. Anagrelid: decade of clinical experinces with its use for the tre atment of primary thrombocythaemi a. Expert Opin Pharmacother 2004; 5: 1781– 1798.

22. Puigdecanet E, Spinet B, Villa O et al. Detecti on of abnormaliti es of PRV-1, TPO, and c- MPL genes detected by fluorescence in situ hybridizati on in essenci al thrombocythemi a. Cancer Genet Cytogenet 2006; 167: 39– 42.

23. Schwarz J, Hrachovinova I, Vorlova Z et al. Thromboembolism in thrombocythemi a pati ents with an additi onal thrombophilic state (Abstr 974). Hematol J 2004; 5(Suppl 2): S321.

24. Silverstein MN, Tefferi A. Tre atment of Essenti al Thrombocythemi a with anagrelid. Semin Hematol 1999; 36: 23– 25.

25. Ste urer M, Gastl G, Jedrzejczak Wet al. Anagrelide for Thrombocytosis in myeloproliferative disorders: a prospective study to assess efficacy and adverse event profile. Cancer 2004; 101: 2239– 2246.

26. Thi ele J, Kvasnicka HM, Vardiman J. Bone marrow histopathology in the di agnosis of chronic myeloproliferative disorders. A forgotten pe arl. Best Pract Res Clin Haematol 2006; 19: 413– 437.

27. Tefferi A, Thi ele J, Orazi A et al. Proposals and rati onale for revisi on of the World He alth Organizati on di agnostic criteri a for polycytemi a vera, Essenti als thrombocythemi a, and primary myelofibrosis: recommendati ons from an ad hoc internati onal expert panel. Blo od 2007; 110: 1092– 1097.

28. Tsimberido u MA, Colburn DE, Welch MA et al. Anagrelid and imatinib mesylate combinati on therapy in pati ents with chronic myeloproliferative disorders. Cancer Chemother Pharmacol 2003; 52: 229– 234.